Akanda vs China SXT Pharmaceuticals
China SXT Pharmaceuticals is the larger business, with $1.1m of revenue in fiscal 2026 against $258,075 for Akanda (4.4 times as much). China SXT Pharmaceuticals grew faster (-34.6% against -69.2%). Akanda kept more of each dollar of sales as profit: a net margin of -467.1% against -545.2%.
| Latest fiscal year | AkandaAKAN, 2025 | China SXT PharmaceuticalsSXTC, 2026 |
|---|---|---|
| Revenue | $258,075 | $1.1m |
| Revenue growth | -69.2% | -34.6% |
| Net income | −$1.2m | −$6.2m |
| Operating margin | -1931.0% | -625.9% |
| Net margin | -467.1% | -545.2% |
| Return on equity | — | -27.5% |
| Free cash flow | −$8.0m | −$4.0m |
| Cash | $504,136 | $28.2m |
| Total debt | $1.0m | $999,565 |
| Debt to equity | — | 3.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $76,159 | $2.0m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 1 sales | 0 buys, 0 sales |